

M. A. Reymond

1 Introduction — 1

M. A. Reymond

2 Peritoneal carcinomatosis: a neglected disease — 5

2.1 An unmet medical need — 5

2.2 Role of the physician in provision of care in advanced peritoneal cancer — 6

2.3 Palliative care in peritoneal carcinomatosis — 7

W. Solass and M. A. Reymond

3 Normal and diseased peritoneum — 11

3.1 Ontology — 11

3.2 Anatomy — 11

3.2.1 Blood supply — 12

3.2.2 Lymphatics — 13

3.2.3 Lymphatic stomata — 13

3.2.4 Milky spots — 14

3.2.5 Greater omentum — 14

3.2.6 Peritoneal nerves — 16

3.3 Physiology of peritoneum — 17

3.3.1 Peritoneum-plasma barrier — 17

3.3.2 Intraperitoneal Hydrostatic Pressure — 18

3.4 Pathophysiology of peritoneal carcinomatosis — 19

3.4.1 Epithelial-mesenchymal transition — 19

3.4.2 Interstitial intratumoral fluid pressure — 21

3.4.3 Ascites — 22

3.4.4 Hormonal changes — 24

W. Solass and M. A. Reymond

4 Diagnosis and staging of peritoneal carcinomatosis — 27

4.1 Diagnostic workup — 27

4.2 Imaging studies — 27

4.2.1 Computer tomography (CT scan) — 28

4.2.2 Magnetic Resonance Imaging (MRI) — 28

4.2.3	Ultrasound —	29
4.2.4	FDG-Positron emission tomography (PET) —	29
4.3	Diagnostic laparoscopy —	30
4.3.1	Peritoneal Cancer Index —	30
4.4	Peritoneal or pleural cytology —	32
4.4.1	Gastric cancer —	32
4.4.2	Ovarian cancer —	33
4.4.3	Colorectal cancer —	33
C. Demtröder, U. Giger-Pabst, W. Solass, and M. A. Reymond		
5	Therapy of peritoneal carcinomatosis —	35
5.1	Systemic palliative chemotherapy —	35
5.2	Intraperitoneal chemotherapy —	36
5.3	Drug uptake into tumoral tissue —	37
5.3.1	Diffusion —	37
5.3.2	Convection —	39
5.4	Effect of peritonectomy on drug clearance —	40
5.5	Influence of intraperitoneal drug concentration —	41
5.6	Tissue penetration of various drugs —	41
5.6.1	Doxorubicin (see also page 199) —	42
5.6.2	Cisplatin (see also page 198) —	43
5.6.3	Oxaliplatin —	43
5.6.4	Taxanes (Paclitaxel, Docetaxel) —	43
5.7	Perioperative intraperitoneal chemotherapy —	44
5.7.1	CHPP —	44
5.7.2	NIPS —	45
5.7.3	EIPL —	46
5.7.4	EPIC —	46
5.8	Intraperitoneal chemotherapy for ascites —	47
5.9	Limitations of intraperitoneal chemotherapy —	47
5.9.1	Poor drug penetration —	47
5.9.2	Poor surface exposition —	48
5.9.3	Local toxicity —	48
5.9.4	Peritoneal sclerosis —	49
5.10	Intraperitoneal immunotherapy —	50
5.10.1	Catumaxomab —	50
5.10.2	Bevacizumab —	51
5.10.3	Immunoradiotherapy —	51
5.11	Intraperitoneal cytolytic virotherapy —	52
5.12	Nanodrugs —	52
5.13	Combined CRS with HIPEC —	53
5.13.1	Cytoreductive surgery (CRS) —	53

5.13.2	Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) —	54
5.13.3	Colorectal cancer —	55
5.13.4	Ovarian Cancer —	56
5.13.5	Gastric Cancer —	56
5.13.6	Learning curve and expertise —	57
5.13.7	Evidence of cost effectiveness —	57
5.13.8	Safety —	58
5.13.9	Indications for CRS and HIPEC —	58

W. Solass and M. A. Reymond

6	Assessing tumor response in peritoneal carcinomatosis —	67
6.1	Natural history of peritoneal carcinomatosis —	67
6.2	RECIST criteria —	67
6.2.1	RECIST criteria in peritoneal carcinomatosis —	68
6.3	Laparoscopy in peritoneal carcinomatosis —	68
6.4	Histology for determining tumor response —	69
6.5	Tumor markers for determining tumor response —	70
6.5.1	Gastric cancer —	70
6.5.2	Ovarian cancer —	70
6.5.3	Colorectal cancer —	71
6.6	Determining clinical benefit rate in peritoneal carcinomatosis —	71

M. A. Reymond, B. Hu, A. Garcia, T. Reck, F. Köckerling, J. Hess, and P. Morel

7	Principle of therapeutic capnoperitoneum —	73
7.1	Material and methods —	74
7.1.1	Design of the prototype —	74
7.2	Results —	75
7.2.1	In vitro trial —	75
7.2.2	In vivo trial —	76
7.3	Discussion —	77
7.3.1	Increasing exposure of the peritoneal surface —	78
7.3.2	Increasing hydrostatic intraabdominal pressure —	78
7.3.3	Applications of therapeutic capnoperitoneum —	79

W. Solass, A. Hetzel, T. Schwarz, G. Nadiradze, E. Sagynaliev, and M. A. Reymond

8	PIPAC Technology —	83
8.1	Aerosol —	83
8.2	Pressure —	86
8.3	Micropump —	86
8.4	High-pressure injector —	87
8.5	Training and documentation —	89
8.6	Limited sales —	89

M. A. Reymond, A. Tannapfel, C. Schneider, H. Scheidbach, S. Köver, A. Jung, T. Reck, H. Lippert, and F. Köckerling

9 Preclinical experiments — 91

- 9.1 Xenograft intraperitoneal model in the pig — **91**
 - 9.1.1 Material and methods — **92**
 - 9.1.2 Anesthesia — **92**
 - 9.1.3 Operative procedure: sigmoid colectomy — **92**
 - 9.1.4 Postoperative care — **93**
 - 9.1.5 Cell line — **93**
 - 9.1.6 Labeling of HeLa cells — **93**
 - 9.1.7 Immunohistochemistry — **94**
 - 9.1.8 In vitro study of chromate toxicity — **94**
 - 9.1.9 Intraoperative complications — **94**
 - 9.1.10 Port site recurrence — **94**
 - 9.1.11 Postoperative course — **95**
 - 9.1.12 Discussion — **96**
- 9.2 Staining experiments with aerosolized methylene blue in the pig — **98**
 - 9.2.1 Introduction — **98**
 - 9.2.2 Material and Methods — **99**
 - 9.2.3 Results — **100**
 - 9.2.4 Discussion — **102**
- 9.3 Ex vivo experiments with Dbait on diseased peritoneum — **106**
 - 9.3.1 Material and methods — **107**
 - 9.3.2 Study design — **108**
 - 9.3.3 Nebulizer — **108**
 - 9.3.4 Patient characteristics, cytoreduction, and intraperitoneal hyperthermic chemotherapy — **109**
 - 9.3.5 Tumor characteristics — **109**
 - 9.3.6 Experimental protocol — **109**
 - 9.3.7 Microscopic analysis — **109**
 - 9.3.8 Results — **110**
 - 9.3.9 Discussion — **112**

W. Solass, R. Kerb, T. Mürdter, U. Giger-Pabst, D. Strumberg, C. Tempfer, J. Zieren, M. Schwab, and M. A. Reymond

10 First PIPAC in-human application — 115

- 10.1 Introduction — **115**
- 10.2 Methods — **115**
 - 10.2.1 Patients — **115**
 - 10.2.2 Surgical procedures — **116**
 - 10.2.3 Safety and Efficacy assessments — **117**
 - 10.2.4 Histology and immunohistochemistry — **117**

10.2.5	Clinical Pharmacology —	117
10.3	Results —	117
10.3.1	Patient 1 —	117
10.3.2	Patient 2 —	118
10.3.3	Patient 3 —	119
10.4	Safety —	121
10.5	Clinical Pharmacology —	121
10.6	Discussion —	122

A. Blanco, U. Giger-Pabst, W. Solass, J. Zieren, and M. A. Reymond

11	Renal and liver toxicities —	127
11.1	Patients and methods —	127
11.1.1	Study Design —	127
11.1.2	Ethics —	128
11.1.3	Patients —	128
11.1.4	Therapy —	128
11.1.5	Sampling —	129
11.2	Statistical Analysis —	129
11.3	Results —	129
11.4	Discussion —	131

C. B. Tempfer, I. Celik, W. Solass, B. Buerkle, U. Giger-Pabst, J. Zieren, D. Strumberg, and M. A. Reymond

12	PIPAC in ovarian cancer —	135
12.1	Off-label use —	135
12.1.1	Patients and methods —	136
12.1.2	Results —	137
12.1.3	Discussion —	140
12.2	PIPAC-OV1: a Phase-2 trial in the third-line palliative situation —	143
12.2.1	Objectives —	143
12.2.2	Study design —	143
12.2.3	Target subject population —	143
12.2.4	Investigational product, dosage, and mode of administration —	144
12.2.5	Duration of treatment —	144
12.2.6	Endpoints —	144
12.2.7	Patient reported outcomes (PROs) —	145
12.2.8	Pharmacokinetics —	145
12.2.9	Safety —	145
12.2.10	Statistical methods —	145
12.2.11	Current stage —	145
12.3	PIPAC-OV2: a Phase-1 dose-finding study —	145
12.4	PIPAC-OV3: a prospective Phase-2-3 randomized trial —	146

G. Nadiradze, W. Solass, J. Zieren, D. Strumberg, M. A. Reymond, and U. Giger-Pabst

13 PIPAC in gastric cancer — 147

13.1 Off-label use — 148

13.2 Results — 149

13.3 Discussion — 154

13.4 PIPAC-GA1: a Phase-2 trial in the third-line palliative situation — 158

13.4.1 Objectives — 158

13.4.2 Study design — 159

13.4.3 Target subject population — 159

13.4.4 Investigational product, dosage and mode of administration — 159

13.4.5 Duration of treatment — 159

13.4.6 Study endpoints — 159

13.4.7 Current stage — 160

U. Giger-Pabst, W. Solass, C. Demtröder, D. Strumberg, J. Zieren, and M. A. Reymond

14 PIPAC in colorectal cancer — 161

14.1 Patients and methods — 162

14.2 Results — 164

14.3 Discussion — 167

W. Solass, U. Giger-Pabst, C. Demtröder, D. Strumberg, J. Zieren, and M. A. Reymond

15 PIPAC in mesothelioma — 171

15.1 Patients and methods — 171

15.2 Results — 172

15.3 Conclusions — 172

K. Odendahl, W. Solass, C. Demtröder, U. Giger-Pabst, C. Tempfer, D. Strumberg, A. Munker, and M. A. Reymond

16 Quality of Life after PIPAC — 175

M. A. Reymond

17 PIPAC and HIPEC — 179

17.1 PIPAC as a neoadjuvant therapy before HIPEC — 181

N. Jonscher, M. Hummels, U. Giger-Pabst, E. Karljalainen, J. Zieren, N. Büchner, M. A. Reymond, and M. Beshay

18 Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) — 183

18.1 Patients — 184

18.2 Technique — 184

18.2.1 First in-human use — 184

18.3 Results — 185

N. Khalili-Harbi, A. Herbette, W. Solass, U. Giger-Pabst, E. Engin, A. Giese, M. Dutreix, and M. A. Reymond

19	Future applications of therapeutic capnoperitoneum — 187
19.1	Study design — 187
19.2	Regulatory background and animals — 187
19.2.1	Staining — 187
19.2.2	Macroscopy — 187
19.2.3	Microscopic analysis — 188
19.3	Pressurized IntraVesical Aerosol Chemotherapy (PIVAC) — 188
19.4	Pressurized IntraLuminal Aerosol Chemotherapy (PILAC) — 190
19.5	Discussion — 192

W. Solass, U. Giger-Pabst, J. Zieren, and M. A. Reymond

20	Occupational health and safety aspects — 195
20.1	Methods — 195
20.1.1	Ethical, legal and regulatory background — 195
20.1.2	Methodology — 195
20.1.3	Nebulizer — 196
20.1.4	Operating room characteristics — 196
20.1.5	Chemotherapy — 197
20.1.6	Experimental protocol — 197
20.2	Results — 198
20.2.1	Identification of hazardous substances and dose — 198
20.2.2	Identification of possible exposure ways — 200
20.2.3	First PIPAC simulation with NaCl 0.9% solution — 200
20.2.4	Second PIPAC simulation with smoke and an artificial leak — 200
20.2.5	Information and training of the team of volunteers — 200
20.2.6	Performance of the first PIPAC procedures with chemotherapy — 201
20.3	Conclusions — 201
20.4	Second assesement — 204
20.5	Biological monitoring — 204

U. Giger-Pabst and M. A. Reymond

21	PIPAC: Risks and dangers — 207
21.1	Bowel access lesions — 207
21.2	Simultaneous PIPAC and cytoreductive surgery — 207
21.3	Port-site metastases — 208
21.4	Tumor invasion of the laparotomy scar — 209
21.5	Subcutaneous toxic emphysema — 209
21.6	Therapy-resistant ascites — 210
21.7	Small bowel obstruction — 210
21.8	Secondary CRS and HIPEC — 211

M. A. Reymond

22 Outlook — 215

- 22.1 Radio- and Chemosensibilizers — 216
- 22.2 Nanodrugs — 216
- 22.3 Multimodal therapy — 216
- 22.4 Preventive application in cancer — 217
- 22.5 Applications outside cancer therapy — 217

U. Giger-Pabst and M. A. Reymond

23 How to start a PIPAC program at your own institution? — 219

- 23.1 Regulatory aspects — 219
 - 23.1.1 Compassionate use program or off-label use? — 219
 - 23.1.2 Drug or medical product? — 220
 - 23.1.3 CE certification — 220
 - 23.1.4 Reimbursement — 220
- 23.2 Technology access — 221
- 23.3 Occupational health and safety — 221
- 23.4 In-house Information and training — 222
- 23.5 Research — 222

U. Giger-Pabst and M. A. Reymond

24 Training and Standard Operating Procedures — 223

- 24.1 Training — 223
- 24.2 Safety checklist for PIPAC — 223
- 24.3 Peritoneal and pleural carcinomatosis index — 225
 - 24.3.1 Extent of Pleural Carcinomatosis (EPC) score — 225
- 24.4 Registry data — 225

Index — 227